tiprankstipranks
Sino Biopharmaceutical Ltd (SBMFF)
OTHER OTC:SBMFF
Holding SBMFF?
Track your performance easily

Sino Biopharmaceutical (SBMFF) Income Statement

28 Followers

Sino Biopharmaceutical Income Statement

Last quarter (Q2 2022), Sino Biopharmaceutical's total revenue was ¥15.19B, an increase of 177.36% from the same quarter last year. In Q2, Sino Biopharmaceutical's net income was ¥―. See Sino Biopharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
¥ 61.93B¥ 26.86B¥ 23.65B¥ 24.23B¥ 20.89B¥ 14.82B
Cost of Revenue
¥ 1.11B¥ 5.33B¥ 5.18B¥ 4.93B¥ 4.20B¥ 3.09B
Gross Profit
¥ 4.41B¥ 21.53B¥ 18.46B¥ 19.31B¥ 16.69B¥ 11.73B
Operating Expense
¥ 3.55B¥ 17.19B¥ 14.05B¥ 13.94B¥ 12.12B¥ 8.46B
Operating Income
¥ 866.85M¥ 4.34B¥ 4.42B¥ 5.36B¥ 4.57B¥ 3.27B
Net Non Operating Interest Income Expense
¥ -71.16M¥ -146.56M¥ -129.37M¥ 27.76M¥ 9.46M¥ 5.11M
Other Income Expense
------
Pretax Income
¥ 1.27B¥ 18.57B¥ 5.01B¥ 5.69B¥ 11.43B¥ 4.20B
Tax Provision
¥ -105.31M¥ 1.96B¥ 672.38M¥ 902.75M¥ 696.24M¥ 542.29M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
¥ 920.59M¥ 14.61B¥ 2.77B¥ 2.76B¥ 9.05B¥ 2.17B
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
¥ 4.65B¥ 22.52B¥ 19.23B¥ 18.87B¥ 16.32B¥ 11.55B
Net Income From Continuing And Discontinued Operation
¥ 920.59M¥ 14.61B¥ 2.77B¥ 2.76B¥ 9.05B¥ 2.17B
Normalized Income
¥ 589.75M¥ 14.59B¥ 2.40B¥ 2.76B¥ 2.84B¥ 2.08B
Interest Expense
¥ 57.91M¥ 308.62M¥ 323.37M¥ 229.95M¥ 153.26M¥ 77.94M
EBIT
¥ 1.33B¥ 18.88B¥ 5.34B¥ 5.92B¥ 11.58B¥ 4.27B
EBITDA
¥ 1.33B¥ 19.87B¥ 6.99B¥ 7.37B¥ 12.76B¥ 4.62B
Currency in CNY

Sino Biopharmaceutical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis